| Recruitment status | Enrolling by invitation |
| Unique ID issued by UMIN | UMIN000027481 |
| Receipt No. | R000031481 |
| Official scientific title of the study | Randomized study of Sokei-Kakketsu-To for the Reduction of Aromatase Inhibitor - Associated Joint Symptoms in Women with Breast Cancer |
| Date of disclosure of the study information | 2017/05/25 |
| Last modified on | 2019/01/07 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Randomized study of Sokei-Kakketsu-To for the Reduction of Aromatase Inhibitor - Associated Joint Symptoms in Women with Breast Cancer | |
| Title of the study (Brief title) | Randomized study of Sokei-Kakketsu-To for the Reduction of Aromatase Inhibitor - Associated Joint Symptoms | |
| Region |
|
|
| Condition | ||||
| Condition | Breast Cancer | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Malignancy | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | Validation of Sokei-Kakketsu-To (TJ-53) for the reduction of aromatase inhibitor associated joint symptoms in women with breast cancer |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Effectiveness in the treatment of TJ-53 to the aromatase inhibitor associated joint symptoms at 3 months. HAQ-DI (Health Assessment Questionnaire-Disability Index) will be used for the assessment of the effectiveness. |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | YES |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | YES |
| Concealment | |
| Intervention | |||
| No. of arms | 2 | ||
| Purpose of intervention | Treatment | ||
| Type of intervention |
|
||
| Interventions/Control_1 | Oral treatment of Sokei-Kakketsu-To(TJ-53) for 3 months | ||
| Interventions/Control_2 | Joint exercises | ||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | Breast cancer patients treated with Aromatase inhibitor(any of Aromatase Inhibitors: Letrozole, Anastrozole and Exemestane) who developed joint symptoms or worsend the symptoms | |||
| Key exclusion criteria | 1. Patients having neurological disorder, collagen disease and orthopedic disease who show the similar joint symptoms.
2. Patients treated with medicine that may affect the joint symptoms (NSAIDs, Acetaminophen or Opioids etc.) |
|||
| Target sample size | 68 | |||
| Research contact person | |
| Name of lead principal investigator | Shinji Ozaki |
| Organization | National Hospital Organization Kure Medical Center/Chugoku Cancer Center |
| Division name | Department of Breast Surgery |
| Address | 3-1 Aoyama-cho, Kure-shi, Hiroshima, JAPAN, 737-0023 |
| TEL | 0823-22-3111 |
| ozakis@kure-nh.go.jp | |
| Public contact | |
| Name of contact person | Shinji Ozaki |
| Organization | National Hospital Organization Kure Medical Center/Chugoku Cancer Center |
| Division name | Department of Breast Surgery |
| Address | 3-1 Aoyama-cho, Kure-shi, Hiroshima, JAPAN, 737-0023 |
| TEL | 0823-22-3111 |
| Homepage URL | |
| ozakis@kure-nh.go.jp | |
| Sponsor | |
| Institute | National Hospital Organization Kure Medical Center/Chugoku Cancer Center |
| Institute | |
| Department | |
| Funding Source | |
| Organization | National Hospital Organization Kure Medical Center/Chugoku Cancer Center |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Enrolling by invitation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000031481 |